News | PET Imaging | July 16, 2020

Novel imaging agent provides foundation to inform treatment strategies

Novel imaging agent provides foundation to inform treatment strategies

Getty Images


July 16, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack. According to research presented at the Society of Nuclear Medicine and Molecular Imaging's 2020 Annual Meeting, the identification of a systemic inflammatory response to myocardial infarction has the potential to assist physicians in identifying patients most at risk of disease progression and most likely to respond to therapy.

Patients with acute myocardial infarction often develop impaired kidney function, thought to be mediated by the activation and mobilization of immune cells, or inflammation. While inflammation is necessary for effective healing, uncontrolled inflammatory cell activity can be detrimental for both the heart and the kidneys. To further understand the mechanics of this bidirectional interaction, researchers conducted a preclinical analysis of a novel imaging agent that targets inflammatory cells after myocardial infarction.

Using serial whole-body CXCR4-targeted 68Ga-pentixafor PET, researchers imaged 65 mice after surgically-induced myocardial infarction or sham surgery at one day, three days, seven days and six weeks. Tracer retention was determined in the kidneys and compared to infarct signal and cardiac function, as measured independently by magnetic resonance.

Cardiac CXCR4 signal was significantly elevated on the first day of imaging and returned to sham level after seven days. Renal CXCR4 signal was unchanged on the first day of imaging, but was reduced after seven days as compared to sham levels. Cardiac and renal signal were directly correlated, suggesting an inflammatory link between the heart and the kidneys. Ex-vivo autoradiography confirmed a significant correlation between tracer retention in the myocardial infarction region and the kidneys.

"This study provides a foundation for simultaneous examination of heart and kidneys after myocardial infarction by using molecular imaging," noted Rudolf Werner, M.D., Ph.D., resident in the department of nuclear medicine at Hannover Medical School in Hannover, Germany. "It provides an impetus for the pursuit of systems-based multi-organ imaging to investigate systemic response to focal injury."

He continued, "Assessment of inflammation after myocardial infarction is beginning to be evaluated in clinical populations. With the growth of long-bore cameras with larger fields of view, the concept of multi-organ imaging will expand substantially in the next years.

In the future, nuclear medicine techniques may identify the optimal patient and time point for anti-inflammatory therapy, and identify the added risk to off-target organs after primary injury."

For more information: www.snmmi.org

 

Related SNMMI20 Content:

SNMMI Channel

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

 

Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiology Business

April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc., GE HealthCare ...

Time April 02, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 21, 2024 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the CIARTIC Move ...

Time March 21, 2024
arrow
News | Information Technology

March 15, 2024 — Visitors to the Philips Booth at HIMSS in Orlando, Fla, experienced smart, scalable and sustainable ...

Time March 15, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and ...

Time March 07, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

February 21, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
Subscribe Now